Apotex (Ferriprox) Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees
  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Apotex (Ferriprox) General Information

Description

Medicinal drug for effective treatment of patients with transfusional iron overload due to thalassemia syndromes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Chiesi Farmaceutici
Primary Office
  • 150 Signet Drive
  • Toronto, Ontario M9L 1T9
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apotex (Ferriprox) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Apotex (Ferriprox)‘s full profile, request access.

Request a free trial

Apotex (Ferriprox) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial